Physician profile
Gerald Benjamin Roth
NPI 1255490322
$3,010.75
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,014 · 2020: $221 · 2021: $74.23 · 2022: $1,075 · 2023: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $627.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $667.92 | 2019-2023 | Fasenra |
| Glaxosmithkline, LLC. | $303.22 | 2019-2023 | Trelegy Ellipta |
| Amgen INC. | $300.01 | 2019-2023 | Prolia, Evenity, Otezla |
| Novo Nordisk INC | $258.50 | 2019-2023 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $215.98 | 2019-2023 | |
| Amarin Pharma, INC. | $147.35 | 2019-2022 | |
| Lilly USA, LLC | $115.68 | 2019-2023 | Mounjaro |
| Abbott Laboratories | $110.95 | 2022-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.34 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $97.88 | 2022 | |
| Nestle Healthcare Nutrition INC. | $85.11 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $69.11 | 2019-2023 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.99 | 2019-2023 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $66.67 | 2022-2023 | Xarelto |
| Abbvie INC. | $63.84 | 2019-2023 | Creon, Linzess |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $48.76 | 2022 | |
| Amneal Pharmaceuticals LLC | $30.92 | 2022-2023 | Unithroid |
| Pfizer INC. | $28.89 | 2019-2020 | |
| Embecta Corp. | $24.29 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Radius Health, INC. | $23.03 | 2023 | Tymlos |
| Horizon Therapeutics Plc | $21.60 | 2023 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $21.38 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.88 | 2023 | Gvoke Hypopen |
| Vanda Pharmaceuticals INC. | $18.57 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.00 | 2022 | |
| Phadia US INC. | $16.55 | 2022 | |
| Sanofi Pasteur INC. | $13.95 | 2023 | |
| Astellas Pharma US INC | $12.79 | 2020 | |
| Gilead Sciences, INC. | $12.46 | 2022 | |
| Acella Pharmaceuticals, LLC | $11.57 | 2020 | |
| Circassia INC. | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.